These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
133 related articles for article (PubMed ID: 36802343)
1. Unfolding and Aggregation Pathways of Variable Domains from Immunoglobulin Light Chains. Meunier-Carmenate Y; Valdés-García G; Maya-Martinez R; French-Pacheco L; Fernández-Silva A; González-Onofre Y; Millan-Pacheco C; Pastor N; Amero C Biochemistry; 2023 Mar; 62(5):1000-1011. PubMed ID: 36802343 [TBL] [Abstract][Full Text] [Related]
2. Effect of single point mutations in a form of systemic amyloidosis. Bhavaraju M; Hansmann UH Protein Sci; 2015 Sep; 24(9):1451-62. PubMed ID: 26105812 [TBL] [Abstract][Full Text] [Related]
3. Kinetic evidence for multiple aggregation pathways in antibody light chain variable domains. Wong S; West ME; Morgan GJ Protein Sci; 2024 Mar; 33(3):e4871. PubMed ID: 38100259 [TBL] [Abstract][Full Text] [Related]
4. Inhibition of amyloid fibril formation in the variable domain of λ6 light chain mutant Wil caused by the interaction between its unfolded state and epigallocatechin-3-O-gallate. Abe Y; Odawara N; Aeimhirunkailas N; Shibata H; Fujisaki N; Tachibana H; Ueda T Biochim Biophys Acta Gen Subj; 2018 Dec; 1862(12):2570-2578. PubMed ID: 30251653 [TBL] [Abstract][Full Text] [Related]
5. Differential effects on light chain amyloid formation depend on mutations and type of glycosaminoglycans. Blancas-Mejía LM; Hammernik J; Marin-Argany M; Ramirez-Alvarado M J Biol Chem; 2015 Feb; 290(8):4953-4965. PubMed ID: 25538238 [TBL] [Abstract][Full Text] [Related]
6. Partially folded intermediates as critical precursors of light chain amyloid fibrils and amorphous aggregates. Khurana R; Gillespie JR; Talapatra A; Minert LJ; Ionescu-Zanetti C; Millett I; Fink AL Biochemistry; 2001 Mar; 40(12):3525-35. PubMed ID: 11297418 [TBL] [Abstract][Full Text] [Related]
7. Domain Interactions Determine the Amyloidogenicity of Antibody Light Chain Mutants. Weber B; Hora M; Kazman P; Pradhan T; Rührnößl F; Reif B; Buchner J J Mol Biol; 2020 Nov; 432(23):6187-6199. PubMed ID: 33058870 [TBL] [Abstract][Full Text] [Related]
8. Mutations can cause light chains to be too stable or too unstable to form amyloid fibrils. Marin-Argany M; Güell-Bosch J; Blancas-Mejía LM; Villegas S; Ramirez-Alvarado M Protein Sci; 2015 Nov; 24(11):1829-40. PubMed ID: 26300552 [TBL] [Abstract][Full Text] [Related]
9. The Kinetic Stability of a Full-Length Antibody Light Chain Dimer Determines whether Endoproteolysis Can Release Amyloidogenic Variable Domains. Morgan GJ; Kelly JW J Mol Biol; 2016 Oct; 428(21):4280-4297. PubMed ID: 27569045 [TBL] [Abstract][Full Text] [Related]
10. Differences in Protein Concentration Dependence for Nucleation and Elongation in Light Chain Amyloid Formation. Blancas-Mejía LM; Misra P; Ramirez-Alvarado M Biochemistry; 2017 Feb; 56(5):757-766. PubMed ID: 28074646 [TBL] [Abstract][Full Text] [Related]
11. Dynamic protein structures in normal function and pathologic misfolding in systemic amyloidosis. Lewkowicz E; Gursky O Biophys Chem; 2022 Jan; 280():106699. PubMed ID: 34773861 [TBL] [Abstract][Full Text] [Related]
13. Immunoglobulin light chain amyloid aggregation. Blancas-Mejia LM; Misra P; Dick CJ; Cooper SA; Redhage KR; Bergman MR; Jordan TL; Maar K; Ramirez-Alvarado M Chem Commun (Camb); 2018 Sep; 54(76):10664-10674. PubMed ID: 30087961 [TBL] [Abstract][Full Text] [Related]
14. Different Dynamics in 6aJL2 Proteins Associated with AL Amyloidosis, a Conformational Disease. Maya-Martinez R; French-Pacheco L; Valdés-García G; Pastor N; Amero C Int J Mol Sci; 2019 Aug; 20(17):. PubMed ID: 31438515 [TBL] [Abstract][Full Text] [Related]
15. In vitro aggregation behavior of a non-amyloidogenic λ light chain dimer deriving from U266 multiple myeloma cells. Arosio P; Owczarz M; Müller-Späth T; Rognoni P; Beeg M; Wu H; Salmona M; Morbidelli M PLoS One; 2012; 7(3):e33372. PubMed ID: 22432016 [TBL] [Abstract][Full Text] [Related]
16. Heat-induced native dimerization prevents amyloid formation by variable domain from immunoglobulin light-chain REI. Nawata M; Tsutsumi H; Kobayashi Y; Unzai S; Mine S; Nakamura T; Uegaki K; Kamikubo H; Kataoka M; Hamada D FEBS J; 2017 Sep; 284(18):3114-3127. PubMed ID: 28736891 [TBL] [Abstract][Full Text] [Related]
17. Kinetic control in protein folding for light chain amyloidosis and the differential effects of somatic mutations. Blancas-Mejía LM; Tischer A; Thompson JR; Tai J; Wang L; Auton M; Ramirez-Alvarado M J Mol Biol; 2014 Jan; 426(2):347-61. PubMed ID: 24157440 [TBL] [Abstract][Full Text] [Related]
18. Decreased amyloidogenicity caused by mutational modulation of surface properties of the immunoglobulin light chain BRE variable domain. Kobayashi Y; Tsutsumi H; Abe T; Ikeda K; Tashiro Y; Unzai S; Kamikubo H; Kataoka M; Hiroaki H; Hamada D Biochemistry; 2014 Aug; 53(31):5162-73. PubMed ID: 25062800 [TBL] [Abstract][Full Text] [Related]
19. Inherent Biophysical Properties Modulate the Toxicity of Soluble Amyloidogenic Light Chains. Maritan M; Romeo M; Oberti L; Sormanni P; Tasaki M; Russo R; Ambrosetti A; Motta P; Rognoni P; Mazzini G; Barbiroli A; Palladini G; Vendruscolo M; Diomede L; Bolognesi M; Merlini G; Lavatelli F; Ricagno S J Mol Biol; 2020 Feb; 432(4):845-860. PubMed ID: 31874151 [TBL] [Abstract][Full Text] [Related]
20. Light chain amyloidosis - current findings and future prospects. Baden EM; Sikkink LA; Ramirez-Alvarado M Curr Protein Pept Sci; 2009 Oct; 10(5):500-508. PubMed ID: 19538145 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]